Imeros

Mepivacaine Hydrochloride, the active ingredient in Imeros, is a local anesthetic presented as a sterile solution for infiltration and perineural use. It provides temporary loss of sensation in targeted tissues, facilitating pain‑free minor surgical, diagnostic, and dental procedures in adult patients.

GNH USA supplies Imeros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics across EU and global markets. The solution is manufactured under strict GMP standards and undergoes rigorous testing to meet European pharmacopeia specifications.

Imeros, a local anesthetic, acts on peripheral nerves to block pain transmission.

Infiltration anesthesia: provides localized numbness for minor surgical or diagnostic procedures. Peripheral nerve block: enables regional anesthesia for limb surgeries. Dental procedures: facilitates pain control during oral surgeries.

Adverse reactions may occur following administration of Imeros.

Common Side Effects: - Transient burning or tingling at the injection site. - Mild dizziness or light‑headedness. - Nausea or mild gastrointestinal discomfort. - Temporary facial or tongue numbness. - Mild headache. - Local swelling or erythema.

Serious or Rare Side Effects: - Cardiac arrhythmias or cardiac arrest. - Central nervous system toxicity, including seizures. - Severe allergic reactions such as anaphylaxis. - Persistent motor block. - Methemoglobinemia (rare). - Respiratory depression.

When using Imeros, consider the following precautions.

Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. Cardiovascular status: use cautiously in patients with heart block or severe arrhythmias. Dosage limits: adhere to the maximum recommended dose to avoid systemic toxicity. Pregnancy: avoid unless the potential benefit outweighs the unknown risk. Elderly patients: monitor for prolonged sensory or motor block. Store at ambient temperature: keep in original container, protect from light and moisture.

Mepivacaine may interact with other medications; monitor patients accordingly.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine): increased cardiotoxicity risk. - Beta‑blockers: may potentiate bradycardia. - General anesthetics such as halothane: enhanced central nervous system depression.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory drugs: may increase bleeding tendency. - Opioids: additive sedation and respiratory depression. - Monoamine oxidase inhibitors: potential for hypertensive crisis.